Copd News

A peakflow meter and daily progress chart, used to supply details of breathing capacity from the lungs.

If you have a chronic lung disease like COPD, you most likely have to see your doctor more often.

Ingen Technologies, Inc. , a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home , Hospital and Aviation industries, announced today that the company has received a purchase order from MedOx Corporation for 40,000 new Oxyview ...

David Koos, Chairman and CEO of Entest BioMedical, Inc. , stated that the Company's unique treatments for Chronic Obstructive Pulmonary Disease , currently in development, can lead to substantial revenue opportunities.

Most Americans are aware of chronic obstructive pulmonary disease , but less than half know that the serious lung disease can be treated, according to national survey results released this week by the U.S. government as part of National COPD Awareness Month in November.

Awareness of COPD-chronic obstructive pulmonary disease-continues to grow in the United States, according to national survey results released today by the National Heart, Lung, and Blood Institute of the National Institutes of Health.

Ingen Technologies, Inc. , a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home , Hospital and Aviation industries, announced today that the CEO, Scott Sand, will discuss conservative projections for 2010 tomorrow, Tuesday ...

Survey: Awareness of COPD - The Nation's Fourth Leading Cause Of Death - Is Rising, But Understanding Is Still Low Smokers and Those At Risk Far Less Likely To Talk To Their Doctor About Symptoms Awareness of COPD - chronic obstructive pulmonary disease - continues to grow in the United States, according to national survey results released today by ...

Patients who used inhaled anticholinergic agents for at least a month to treat their chronic obstructive pulmonary disease showed a 58% increase in risk of cardiovascular death, myocardial infarction, or stroke, when compared with those who took a placebo or other inhaled agents, according to the results of a 17-trial meta-analysis published in the ...

Cigarette smoking is the most prominent risk factor for chronic obstructive pulmonary disease and peripheral arterial disease .

The fourth leading cause of death in the United States is Chronic Obstructive Pulmonary Disease , a lung disease that includes chronic bronchitis and emphysema.

Main Category: Respiratory / Asthma Also Included In: Pharma Industry / Biotech Industry Infectious Diseases / Bacteria / Viruses Sosei Group Corporation , announces that the Phase III trials with NVA237, which commenced in June 2009, are proceeding to plan.

The Company is involved with the development of testing procedures for diabetes, stem cell research applications for diabetes, traumatic brain injury and other illnesses.

Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.

In patients with chronic obstructive pulmonary disease , triple therapy with budesonide/formoterol added to tiotropium significantly improves lung function and reduces severe exacerbations compared to monotherapy with tiotropium, according to a study published in the Oct.

Bio-Matrix Scientific Group, Inc. provided a progress report on the Companya s previously announced new opportunities.

Patients with moderate to severe chronic obstructive pulmonary disease can benefit from triple therapy that includes a long-acting I2-agonist , an inhaled corticosteroid and an anti-muscarinic agent, according to researchers in Germany.

In a key development, the Ministry of Health and Family Welfare has urged asthma & COPD patients and health professionals to adopt environment friendly asthma and COPD inhalers.

The National Heart, Lung, and Blood Institute of the National Institutes of Health has approved the award of 15 contracts under its communications contract with Porter Novelli totaling $462,000 to leading community-based lung health organizations from New Hampshire to California to support efforts to improve awareness and understanding of COPD , ...

Formoterol is increasingly viewed as the long-acting I22-agonist of choice by pharmaceutical companies wishing to participate in the dynamic inhaled corticosteroid plus long-acting I22-agonist combination therapy segment of the asthma and chronic obstructive pulmonary disease market.